Abstract
Lymphoplasmacytic lymphoma is an exclusion diagnosis and is defined as a neoplasia occurring in older adults in which bone marrow (less frequently lymph nodes and spleen) is infiltrated by B lymphocytes, plasmacytoid lymphocytes, or plasma cells without the fulfillment of diagnostic criteria for any other small B-cell lymphoid neoplasm with putative plasmacytic differentiation (World Health Organization, WHO classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition. International Agency for Research on Cancer, Lyon, 2017). With the presence of an additional monoclonal immunoglobulin M (IgM) gradient, the disease is called Waldenström’s macroglobulinemia (WM).
Since the first report by Jan Waldenström in 1944, after whom the disease was later named, symptomatic cytopenia, hyperviscosity, and globulin/serum protein excess have been described as disease characteristics (Waldenstrom J, Acta Med Scand 117:216–247, 1944).
This is a preview of subscription content, log in via an institution to check access.
References
Anagnostopoulos A, Hari PN, Pérez WS, et al. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom’s macroglobulinemia. Biol Blood Marrow Transplant. 2006;12:845–54. https://doi.org/10.1016/j.bbmt.2006.04.010.
Anderson LD, Sandmaier BM, Maris MB, et al. Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) for refractory Waldenstrom’s macroglobulinemia (WM): evidence for a Graft-Versus-WM effect. Blood. 2006;108:3034.
Buske C, Leblond V, Dimopoulos M, et al. Waldenstrom’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi155–9. https://doi.org/10.1093/annonc/mdt298.
Castillo JJ, Olszewski AJ, Kanan S, et al. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol. 2015;169:81–9. https://doi.org/10.1111/bjh.13264.
Castillo JJ, Garcia-Sanz R, Hatjiharissi E, et al. Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. Br J Haematol. 2016;175:77–86. https://doi.org/10.1111/bjh.14196.
Davda R, Davies S, Kumaran T. Splenic irradiation in the management of Waldenstrom macroglobulinemia. Leuk Lymphoma. 2009;50:1047–9. https://doi.org/10.1080/10428190902898263.
Dimopoulos MA, Anagnostopoulos A. Treatment of Waldenstrom’s macroglobulinemia. Curr Treat Options in Oncol. 2007;8:144–53. https://doi.org/10.1007/s11864-007-0016-2.
Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and management of Waldenstrom’s macroglobulinemia. J Clin Oncol. 2005;23:1564–77. https://doi.org/10.1200/JCO.2005.03.144.
Dreger P, Glass B, Kuse R, et al. Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenström’s macroglobulinaemia. Br J Haematol. 1999;106:115–8.
Duchesne GM, Harmer CL. Hemibody irradiation in lymphomas and related malignancies. Int J Radiat Oncol. 1985;11:2003–6. https://doi.org/10.1016/0360-3016(85)90284-6.
Herrinton L, Weiss N. Incidence of Waldenstrom’s macroglobulinemia. Blood. 1993;82:3148.
Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991;77:649–53.
Kastritis E, Kyrtsonis M-C, Hadjiharissi E, et al. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom’s macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leuk Res. 2010;34:1340–3. https://doi.org/10.1016/j.leukres.2010.04.005.
Kastritis E, Kyrtsonis M-C, Hatjiharissi E, et al. No significant improvement in the outcome of patients with Waldenström’s macroglobulinemia treated over the last 25 years. Am J Hematol. 2011;86:479–83. https://doi.org/10.1002/ajh.22027.
Kristinsson SY, Bjorkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. Blood. 2008;112:3052–6. https://doi.org/10.1182/blood-2008-06-162768.
Kristinsson SY, Björkholm M, Landgren O. Survival in monoclonal gammopathy of undetermined significance and Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013a;13:187–90. https://doi.org/10.1016/j.clml.2013.02.010.
Kristinsson SY, Eloranta S, Dickman PW, et al. Patterns of survival in lymphoplasmacytic lymphoma/waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005. Am J Hematol. 2013b;88:60–5. https://doi.org/10.1002/ajh.23351.
Kyriakou C, Canals C, Cornelissen JJ, et al. Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28:4926–34. https://doi.org/10.1200/JCO.2009.27.3607.
Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenström’s Macroglobulinemia. Blood. 2016;128:1321–8. https://doi.org/10.1182/blood-2016-04-711234.
Martino R, Shah A, Romero P, et al. Allogeneic bone marrow transplantation for advanced Waldenstrom’s macroglobulinemia. Bone Marrow Transplant. 1999;23:747–9. https://doi.org/10.1038/sj.bmt.1701633.
Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113:4163–70. https://doi.org/10.1182/blood-2008-08-174961.
Nakashima H, Saito B, Ariizumi H, et al. Splenic irradiation as a successful treatment for an elderly patient with B-cell prolymphocytic leukemia. Rinsho Ketsueki. 2008;49:1619–22.
Sekhar J, Sanfilippo K, Zhang Q, et al. Waldenström macroglobulinemia: a surveillance, epidemiology, and end results database review from 1988 to 2005. Leuk Lymphoma. 2012;53:1625–6. https://doi.org/10.3109/10428194.2012.656103.
Takemori N, Hirai K, Onodera R, et al. Durable remission after splenectomy for Waldenström’s macroglobulinemia with massive splenomegaly in leukemic phase. Leuk Lymphoma. 1997;26:387–93. https://doi.org/10.3109/10428199709051789.
Tournilhac O, Leblond V, Tabrizi R, et al. Transplantation in Waldenstrom’s macroglobulinemia – the French experience. Semin Oncol. 2003;30:291–6. https://doi.org/10.1053/sonc.2003.50048.
Waldenstrom J. Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia – a new syndrome? Acta Med Scand. 1944;117:216–47. https://doi.org/10.1111/j.0954-6820.1944.tb03955.x.
Wang H, Chen Y, Li F, et al. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer. 2012;118:3793–800. https://doi.org/10.1002/cncr.26627.
Wei Z, Yanxia Y, Ying X, et al. Splenic re-irradiation for waldenstrőm’s macroglobulinemia. Radiat Oncol Lond Engl. 2012;7:58. https://doi.org/10.1186/1748-717X-7-58.
World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition. Lyon: International Agency for Research on Cancer; 2017.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this entry
Cite this entry
Oertel, M., Micke, O., Eich, H.T. (2018). Radiation Therapy in Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia). In: Wenz, F. (eds) Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-52619-5_26-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-52619-5_26-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-52619-5
Online ISBN: 978-3-319-52619-5
eBook Packages: Springer Reference MedicineReference Module Medicine